Author

T. F. Omansen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:mouse· 3 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

D. Almeida· 3 shared E. Nuermberger· 3 shared P. J. Converse· 3 shared J. H. Grosset· 1 shared J. kim· 1 shared J. Lee· 1 shared O. Komm· 1 shared R. Tasneen· 1 shared

Activity by Year

2018-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

D. Almeida

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Ultrashort treatment with telacebec alone and with companion drugs in immunocompetent and immunosuppressed mouse footpad models of Buruli ulcer

P. J. Converse, O. Komm, D. Almeida, T. F. Omansen, E. Nuermberger

This study evaluates the efficacy of telacebec alone and with companion drugs in reducing treatment duration for Buruli ulcer in immunocompetent and immunosuppressed mice.

bioRxiv · Jun 22, 2021 · PreprintMicrobiology

Telacebec for ultra-short treatment of Buruli ulcer in a mouse model

D. Almeida, P. J. Converse, T. F. Omansen, S. TYAGI, R. Tasneen, J. kim, E. Nuermberger

This study evaluates Telacebec's efficacy in shortening Buruli ulcer treatment in mice, showing it can cure infections in as little as 1 week with no relapse.

bioRxiv · Feb 10, 2020Microbiology

High-dose rifamycins enable shorter oral treatment in a murine model of Mycobacterium ulcerans disease

T. F. Omansen, D. Almeida, P. J. Converse, S.-Y. Li, J. Lee, Y. Stienstra, T. S. van der Werf, J. H. Grosset, E. Nuermberger

This study evaluates higher doses of rifamycins in a mouse model of Buruli ulcer, finding dose-dependent efficacy and potential for shorter treatment regimens.

bioRxiv · Aug 19, 2018Microbiology